2269 Stock Overview
An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
WuXi Biologics (Cayman) Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$15.02 |
| 52 Week High | HK$49.70 |
| 52 Week Low | HK$10.14 |
| Beta | 0.61 |
| 11 Month Change | -8.97% |
| 3 Month Change | 26.01% |
| 1 Year Change | -68.21% |
| 33 Year Change | -86.42% |
| 5 Year Change | -50.73% |
| Change since IPO | 59.50% |
Recent News & Updates
Recent updates
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar
Sep 26
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet
Sep 12Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why
Jun 12Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%
Jun 11Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding
Jun 11Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly
Apr 15Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge
Mar 04Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade
Dec 08Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Nov 26Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
Nov 10What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?
Sep 26These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well
Aug 26WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate
Aug 10Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?
Jun 19Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)
May 12Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?
Mar 25At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?
Mar 13Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?
Feb 13An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued
Jan 30Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?
Dec 09Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching
Nov 20With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case
Nov 08Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?
Oct 27WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly
Sep 08Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?
Aug 15Shareholder Returns
| 2269 | HK Life Sciences | HK Market | |
|---|---|---|---|
| 7D | -12.3% | -8.1% | -5.3% |
| 1Y | -68.2% | -57.8% | 11.3% |
Return vs Industry: 2269 underperformed the Hong Kong Life Sciences industry which returned -57.8% over the past year.
Return vs Market: 2269 underperformed the Hong Kong Market which returned 11.3% over the past year.
Price Volatility
| 2269 volatility | |
|---|---|
| 2269 Average Weekly Movement | 12.5% |
| Life Sciences Industry Average Movement | 14.4% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 19.1% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 2269 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 2269's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 12,435 | Chris Chen | www.wuxibiologics.com |
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh.
WuXi Biologics (Cayman) Inc. Fundamentals Summary
| 2269 fundamental statistics | |
|---|---|
| Market cap | HK$61.65b |
| Earnings (TTM) | HK$2.83b |
| Revenue (TTM) | HK$18.43b |
21.7x
P/E Ratio3.3x
P/S RatioIs 2269 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2269 income statement (TTM) | |
|---|---|
| Revenue | CN¥17.12b |
| Cost of Revenue | CN¥10.50b |
| Gross Profit | CN¥6.62b |
| Other Expenses | CN¥3.99b |
| Earnings | CN¥2.63b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.64 |
| Gross Margin | 38.66% |
| Net Profit Margin | 15.38% |
| Debt/Equity Ratio | 4.8% |
How did 2269 perform over the long term?
See historical performance and comparison